Shandong Xinhua Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Shandong Xinhua Pharmaceutical yıllık ortalama 11.4% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 5.7% annual. Gelirler growing yılda ortalama 9.5% oranında artmaktadır. Shandong Xinhua Pharmaceutical'in özkaynak karlılığı 9.1% ve net marjı 5.4%'dir.

Anahtar bilgiler

11.4%

Kazanç büyüme oranı

9.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.6%
Gelir büyüme oranı	9.5%
Özkaynak getirisi	9.1%
Net Marj	5.4%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26

Gelir ve Gider Dağılımı

Shandong Xinhua Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:719 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	8,337	449	1,097	405
30 Jun 24	8,161	492	1,155	427
31 Mar 24	7,936	487	1,189	449
31 Dec 23	8,101	497	1,298	419
30 Sep 23	8,547	510	1,354	428
30 Jun 23	8,511	486	1,347	413
31 Mar 23	8,311	454	1,325	379
01 Jan 23	7,503	411	1,111	346
30 Sep 22	7,073	357	980	352
30 Jun 22	6,673	343	900	340
31 Mar 22	6,623	357	908	343
31 Dec 21	6,560	349	931	341
30 Sep 21	6,307	364	935	338
30 Jun 21	6,271	353	992	311
31 Mar 21	6,068	339	957	301
31 Dec 20	6,006	325	944	298
30 Sep 20	5,814	305	982	261
30 Jun 20	5,769	323	990	260
31 Mar 20	5,682	310	1,049	253
31 Dec 19	5,606	300	1,105	235
30 Sep 19	5,716	303	1,107	229
30 Jun 19	5,680	281	1,072	233
31 Mar 19	5,457	264	1,012	201
31 Dec 18	5,245	255	924	187
30 Sep 18	5,023	229	859	172
30 Jun 18	4,800	226	809	151
31 Mar 18	4,638	226	710	204
31 Dec 17	4,516	210	725	161
30 Sep 17	4,491	207	718	130
30 Jun 17	4,420	183	762	97
31 Mar 17	4,306	154	799	0
31 Dec 16	4,015	122	724	0
30 Sep 16	3,800	110	667	0
30 Jun 16	3,647	103	624	0
31 Mar 16	3,602	89	611	0
31 Dec 15	3,597	83	611	0
30 Sep 15	3,604	64	613	0
30 Jun 15	3,678	36	593	0
31 Mar 15	3,653	62	604	0
31 Dec 14	3,590	51	565	0
30 Sep 14	3,769	52	614	0
30 Jun 14	3,635	74	589	0
31 Mar 14	3,588	50	544	0
31 Dec 13	3,391	39	501	0

Kaliteli Kazançlar: 719 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 719 'nin mevcut net kar marjları (5.4%) geçen yılın (6%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 719 şirketinin kazancı son 5 yılda yılda 11.4% oranında arttı.

Büyüme Hızlandırma: 719 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 719 geçtiğimiz yıl negatif kazanç büyümesine ( -12% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 6.4% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 719 'nin Özsermaye Getirisi ( 9.1% ) düşük olarak değerlendiriliyor.

Shandong Xinhua Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Recent updates

Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application

Investor sentiment improves as stock rises 16%

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application

Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs

Upcoming dividend of HK$0.027 per share

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Dividend of HK$0.27 announced

Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 21% overvalued

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.6% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Now 21% undervalued after recent price drop